Organogenesis VP amends Form 4 equity grant
Organogenesis Holdings Inc. executive Robert Cavorsi, Vice President of Strategy, filed an amended insider report updating a prior Form 4.
Rhea-AI Filing Summary
Organogenesis Holdings Inc. executive Robert Cavorsi, Vice President of Strategy, filed an amended insider report updating a prior Form 4. The amendment corrects the number of Class A Common Stock shares acquired upon vesting and settlement of a performance share award and the shares withheld for taxes. On February 18, 2026, he was granted 16,454 shares at $0.00 per share and had 5,487 shares withheld at $3.84 per share to satisfy tax obligations. Following these adjustments, his direct holdings total 276,224 Class A shares. The filing states no other changes were made to the original report.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Class A Common Stock | 16,454 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Class A Common Stock | 5,487 | $3.84 | $21K |
Footnotes (1)
- F1. This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the amended Form 4 for Organogenesis (ORGO) report about Robert Cavorsi?
Does the Organogenesis (ORGO) amended Form 4 add any new insider trades?
Why was the original Organogenesis (ORGO) Form 4 for Robert Cavorsi corrected?
AI-generated analysis. How Rhea-AI works. Not financial advice.